Regenerative wound healing
People with chronic wounds deserve more than wound management, they deserve healing.
Omnio’s plasminogen-based therapy accelerates the body’s natural healing process in chronic wounds:
Stopping infection, relieving pain, and restoring tissue where the current standard of care fails.
Regenerative wound healing
People with chronic wounds deserve more than wound management, they deserve healing.
Omnio’s plasminogen-based therapy accelerates the body’s natural healing process in chronic wounds:
Stopping infection, relieving pain, and restoring tissue where the current standard of care fails.
Every 20 seconds...
Someone loses a limb due to a chronic wound.
An estimated 167 million people with diabetes will develop diabetic foot ulcers (DFUs), and about one-third of these will become hard-to-heal chronic wounds.
Despite best efforts, standard treatments fall short for hard-to-heal diabetic wounds—contributing to amputation in 1 out of every 5 cases.
Healthcare systems in Europe and the US alone spend over €80-90 billion annually treating chronic wounds.
At the forefront of innovation, Omnio is the first to introduce a next-generation therapy powered by a recombinant plasminogen-based drug—stable, scalable, and regenerative
What specialists are saying
Early feedback from wound care specialists highlights the potential of Omnio’s recombinant plasminogen in patients
with chronic wounds that failed to respond to four weeks of conventional therapy:
"Plasminogen is a novel and vital tool that could change our view on the wound healing process." Due to its upstart and conduct of several functions that is necessary for a regular wound healing process. Once we can observe that it is responsible for a start of the wound healing process we can also expect it to close it in a regulatory way. This wound healing gives us several advantages both to the patient with less pain and odour, and to the caregiver with reliability and trust." Read more
Our Breakthrough
Healing from the Inside Out
At the core of Omnio’s therapy is plasminogen — a natural protein that helps your body clear damaged tissue, fight infection, and regenerate skin. In people with chronic wounds, that healing process stalls.
Omnio restarts it.
Omnio’s preclinical results:
- 65–70% complete healing in early studies
- Active against antibiotic-resistant infections (e.g., MRSA)
- Reduces pain, inflammation, and amputation risk
- Safe, targeted, and easy to administer
Our Breakthrough
Healing from the Inside Out
At the core of Omnio’s therapy is plasminogen — a natural protein that helps your body clear damaged tissue,
fight infection, and regenerate skin. In people with chronic wounds, that healing process stalls.
Omnio restarts it.
Omnio’s early internal preclinical data and product design suggest that
our recombinant plasminogen has the potential to offer:
- 65–70% complete healing in early studies
- Active against antibiotic-resistant infections (e.g., MRSA)
- Reduces pain, inflammation, and amputation risk
- Safe, targeted, and easy to administer
What makes Omnio unique
Omnio doesn’t just manage wounds. It helps the body heal them.
so it leads to a meaningful reduction
in overall treatment costs
Our Timeline
A multi-Billion Opportunity
Capturing unmet demand in chronic wound care.
Capturing unmet demand in chronic wound careDiabetic foot ulcers are one of healthcare’s most urgent and expensive challenges.
Omnio targets the hardest-to-heal cases, where current treatments fail and costs skyrocket.
- 12.3 million DFUs cases annually
- 30% of these will become hard to heal wounds
- €1.2Billion annual revenue from Omnio’s plasminogen within 5 years of launch
- Omnio’s recombinant plasminogen not only for DFUs, but a broad platform for wound & inflammation
Science-Backed
Patient-Driven
Our therapy is rooted in biology, supported by decades of research, and built for real-world impact.
- Scientifically Sound: Omnio’s own studies demonstrate Omnio’s Rec-PLG drug candidate accelerates
wound healing and activates defence against infection including antibiotic resistant bacteria. - Manufacturing-ready: Production is being established in line with GMP requirements, scalable, and reproducible
- Aligned with human biology: No synthetic growth factors or gene edits
- Simple to apply: Subcutaneous injection, no surgery, no complexity
The science is solid. The solution is real. The impact is coming.
Who We’re Helping
Patients facing chronic diabetic wound ulcers that resist healing — and the clinicians who work relentlessly to make a difference.
Chronic wounds can rob people of mobility, dignity, and independence.
Omnio is made for those for which all usual care has failed and are still waiting for a solution.
Omnio’s Rec-PLG helps patients regain a normal life and purpose.
We begin with diabetic foot ulcers, but our approach applies to a wide range of hard-to-heal wounds.
Our Vision
Chronic wounds should be a thing of the past.
We believe in a future where no one loses their mobility, independence, or quality of life to a wound that won’t heal.
Omnio is working to make that future a reality.
By restoring the body’s natural healing process, we’re not just closing wounds, we’re restoring lives.
Let’s Talk
Whether you’re a clinician, researcher, or investor, we’re building the future of regenerative healing together.
Omnio is ready to scale. We’re looking for partners who believe in better outcomes for patients and are ready to help us bring this therapy to the people who need it most.
